Alyeska Investment Group
GEVA

Alyeska Investment Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Alyeska Investment Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,000
Closed -$1.03M – 588
2014
Q3 		$1.03M Buy
+15,000
New +$1.07M 0.02% 324
2014
Q2 		– Sell
-14,249
Closed -$1.18M – 493
2014
Q1 		$1.18M Buy
+14,249
New +$1.32M 0.03% 288

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Alyeska Investment Group's GEVA Position: Q4 2014 in Review

Alyeska Investment Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2014, closing a stake of 15,000 shares — an estimated $1.03M sold.

Alyeska Investment Group first reported a position in GEVA in Q1 2014 and held it in 2 quarters. The position peaked at $1.18M in Q1 2014. 126 funds tracked by Wall St. Rank hold GEVA as of Q4 2014.

  • Alyeska Investment Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • Alyeska Investment Group sold 15,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2014, an estimated $1.03M.
  • Alyeska Investment Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 2 quarters.
  • Alyeska Investment Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.18M in Q1 2014.
  • 126 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2014.

Based on Alyeska Investment Group's 13F filing for Q4 2014, filed 17 Feb 2015.